Crown J, O’Leary M (2000) The taxanes: an update. Lancet 355(9210):1176–1178. https://doi.org/10.1016/S0140-6736(00)02074-2

Article  CAS  PubMed  Google Scholar 

Montero A, Fossella F, Hortobagyi G, Valero V (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6(4):229–239. https://doi.org/10.1016/S1470-2045(05)70094-2

Article  CAS  PubMed  Google Scholar 

Felici A, Verweij J, Sparreboom A (2002) Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer 38(13):1677–1684. https://doi.org/10.1016/s0959-8049(02)00151-x

Article  CAS  PubMed  Google Scholar 

Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH (2000) The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 6(4):1255–1258

CAS  PubMed  Google Scholar 

Puisset F, Alexandre J, Treluyer JM, Raoul V, Roche H, Goldwasser F, Chatelut E (2007) Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 97(3):290–296. https://doi.org/10.1038/sj.bjc.6603872

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB (1998) Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncology: Official J Am Soc Clin Oncol 16(1):187–196. https://doi.org/10.1200/JCO.1998.16.1.187

Article  CAS  Google Scholar 

Kushnir I, Mallick R, Ong M, Canil C, Bossé D, Koczka K, Reaume NM (2020) Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer. Cancer Chemother Pharmacol 85(5):863–868. https://doi.org/10.1007/s00280-020-04063-7

Article  CAS  PubMed  Google Scholar 

James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O’Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK (2016) investigators S Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387 (10024):1163–1177. https://doi.org/10.1016/S0140-6736(15)01037-5

Hohmann N, Haefeli WE, Mikus G (2015) Use of Microdose phenotyping to Individualise Dosing of patients. Clin Pharmacokinet 54(9):893–900. https://doi.org/10.1007/s40262-015-0278-y

Article  CAS  PubMed  Google Scholar 

van der Heijden L, van Nuland M, Beijnen J, Huitema A, Dorlo T (2023) A naïve pooled data approach for extrapolation of phase 0 microdose trials to therapeutic dosing regimens. Clin Transl Sci 16(2):258–268. https://doi.org/10.1111/cts.13446

Article  CAS  PubMed  Google Scholar 

Boosman RJ, de Rouw N, Huitema ADR, Burgers JA, ter Heine R (2023) Prediction of the pharmacokinetics of pemetrexed with a low test dose: a proof-of-concept study. Br J Clin Pharmacol 89(2):699–704. https://doi.org/10.1111/bcp.15520

Article  CAS  PubMed  Google Scholar 

Lappin G, Noveck R, Burt T (2013) Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol 9(7):817–834. https://doi.org/10.1517/17425255.2013.786042

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rowland M (2012) Microdosing: a critical assessment of human data. J Pharm Sci 101(11):4067–4074. https://doi.org/10.1002/jps.23290

Article  CAS  PubMed  Google Scholar 

Clarke SJ, Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36(2):99–114. https://doi.org/10.2165/00003088-199936020-00002

Article  CAS  PubMed  Google Scholar 

Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, Dong J, Ruiz-Garcia A, Sweeney K, Cronenberger C (2013) Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol 2(7):e51. https://doi.org/10.1038/psp.2013.26

Article  CAS  PubMed  Google Scholar 

Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303–332. https://doi.org/10.1146/annurev.pharmtox.48.113006.094708

Article  CAS  PubMed  Google Scholar 

Fujita K, Yoshino E, Kawara K, Maeda K, Kusuhara H, Sugiyama Y, Yokoyama T, Kaneta T, Ishida H, Sasaki Y (2015) A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer. Cancer Chemother Pharmacol 76(4):793–801. https://doi.org/10.1007/s00280-015-2844-2

Article  CAS  PubMed  Google Scholar 

van der Veldt AA, Lubberink M, Mathijssen RH, Loos WJ, Herder GJ, Greuter HN, Comans EF, Rutten HB, Eriksson J, Windhorst AD, Hendrikse NH, Postmus PE, Smit EF, Lammertsma AA (2013) Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [(1)(1)C]docetaxel and positron emission tomography. Clin Cancer Res 19(15):4163–4173. https://doi.org/10.1158/1078-0432.CCR-12-3779

Article  CAS  PubMed  Google Scholar 

Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB (1996) A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 24(2):153–172. https://doi.org/10.1007/BF02353487

Article  CAS  PubMed  Google Scholar 

Crombag MBS, Dorlo TPC, van der Pan E, van Straten A, Bergman AM, van Erp NP, Beijnen JH, Huitema ADR (2019) Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. Pharm Res 36(12):181. https://doi.org/10.1007/s11095-019-2706-4

Article  CAS  PubMed  Google Scholar 

Minami H, Kawada K, Sasaki Y, Tahara M, Igarashi T, Itoh K, Fujii H, Saeki T, Ozawa K, Sato H (2009) Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci 100(1):144–149. https://doi.org/10.1111/j.1349-7006.2009.00992.x

Article  CAS  PubMed  Google Scholar 

Bosgra S, Vlaming ML, Vaes WH (2016) To apply Microdosing or not? Recommendations to single out compounds with non-linear pharmacokinetics. Clin Pharmacokinet 55(1):1–15. https://doi.org/10.1007/s40262-015-0308-9

Article  CAS  PubMed  Google Scholar 

Engels FK, Loos WJ, van der Bol JM, de Bruijn P, Mathijssen RH, Verweij J, Mathot RA (2011) Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res 17(2):353–362. https://doi.org/10.1158/1078-0432.CCR-10-1636

Article  CAS  PubMed  Google Scholar 

Lombard A, Mistry H, Aarons L, Ogungbenro K (2021) Dose individualisation in oncology using chemotherapy-induced neutropenia: example of docetaxel in non-small cell lung cancer patients. Br J Clin Pharmacol 87(4):2053–2063. https://doi.org/10.1111/bcp.14614

Article  CAS  PubMed  Google Scholar